GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (STU:YB4P) » Definitions » Inventories, Other

Savara (STU:YB4P) Inventories, Other : €0.00 Mil (As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Savara Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Savara's other inventories for the quarter that ended in Jun. 2024 was €0.00 Mil.


Savara Inventories, Other Historical Data

The historical data trend for Savara's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savara Inventories, Other Chart

Savara Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Savara Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Savara Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Savara Business Description

Traded in Other Exchanges
Address
1717 Langhorne Newtown Road, Suite 300, Langhorne, PA, USA, 78746
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Savara Headlines

No Headlines